Malignant tumor
Conditions
Interventions
Case series:Preventive use of recombinant human thrombopoietin
Sponsors
Ordos Central Hospital, Inner Mongolia
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) normal platelet count at baseline (>=100x10^9 /L); 2) CIT of grade 2 or more in the last treatment cycle, with recovery to normal level before the next prophylactic cycle; 3) same regimen and dose intensity as in the prophylactic cycle; 4) no hematological diseases that influence blood platelet number; 5) normal liver and kidney function and normal prothrombin time; 6) no severe cardiopulmonary dysfunction; 7) a Karnofsky Performance Status (KPS) score greater than 80.
Exclusion criteria
Exclusion criteria: 1) changed chemotherapy regimen or decreased dose by more than 10% due to severe side effects in the next cycle; 2) poor compliance and dropout; 3) CIT of grade 2 or more in the last treatment cycle, with no recovery to normal level before the next prophylactic cycle; 4) hematological system diseases that influence hematopoietic function; 5) recent administration of drugs that influence hematopoiesis; 6) severe respiratory and circulatory diseases; 7) a KPS score lower than 80.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet count; | — |
Countries
China
Contacts
Public ContactLi Quanfu
Ordos Central Hospital
Outcome results
None listed